Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate the Safety and Immunogenicity of Monovalent OPV2 in Children Aged 1 to 5 Years in Lithuania

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. 1 to 5 years of age, previously vaccinated with three or four doses of IPV.~2. Healthy without obvious medical conditions that preclude entry of the subject into the study as established by the medical history and physical examination.~3. Written informed consent obtained from 1 or 2 parent(s) or legal guardian(s) as per country regulations.~Exclusion Criteria:~1. Previous vaccination against poliovirus outside the national immunization schedule.~2. Any confirmed or suspected immunosuppressive or known immunodeficient condition including human immunodeficiency virus (HIV) infection.~3. Family history of congenital or hereditary immunodeficiency.~4. Major congenital defects or serious uncontrolled chronic illness (neurologic, pulmonary, gastrointestinal, hepatic, renal, or endocrine).~5. Known allergy to any component of the study vaccines or to any antibiotics.~6. Administration of immunoglobulins and/or any blood products since birth or planned administration during the study period.~7. Acute severe febrile illness at day of vaccination deemed by the Investigator to be a contraindication for vaccination (the child can be included at a later time if within age window and all in/exclusion criteria are met.).~8. Member of the subject's household (living in the same house or apartment unit) has received OPV in the last 3 months.~9. Subject who, in the opinion of the Investigator, is unlikely to comply with the protocol or is inappropriate to be included in the study for the safety or the benefit-risk ratio of the subject.

- Gender: ALL
- Minimum Age: 1 Year
- Maximum Age: 5 Years
- Healthy Volunteers: t

Study Arms:
- Sabin mOPV2 1 dose (Type: EXPERIMENTAL): IPV-vaccinated children to receive 1 dose of SABIN mOPV2 (Group 1)
- SABIN mOPV2 2 doses (Type: EXPERIMENTAL): IPV-vaccinated children to receive 2 doses of SABIN mOPV2 (Group 2)

Based on this trial design, predict the completion outcome and termination type (if applicable).